期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 41, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13046-022-02273-w
关键词
Pancreatic cancer; Immune checkpoint inhibitor; PD-1; PD-L1; Combinational therapy; Systematic treatment; Post-translational modification; Precision therapy
类别
资金
- National Natural Science Foundation of China [81871925, 82071867]
- Fundamental Research Funds for the Zhejiang Provincial Universities [2021XZZX031]
- Key Research and Development Program of Zhejiang Province [2020C03117]
Pancreatic cancer has a high mortality rate and immunotherapy with anti-PD-(L)1 has limited efficacy. This review explores the combination of chemotherapy, radiotherapy, targeted therapy, and immunotherapy with anti-PD-(L)1 in pancreatic cancer treatment. It also suggests future directions for optimizing combination therapy.
Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5-10%. Immunotherapy, represented by the blocking antibodies against programmed cell death protein 1 or its ligand 1 (anti-PD-(L)1), has achieved remarkable success in a number of malignancies. However, due to the immune-suppressive tumor microenvironment, the therapeutic efficacy of anti-PD-(L)1 in pancreatic cancer is far from expectation. To address such a fundamental issue, chemotherapy, radiotherapy, targeted therapy and even immunotherapy itself, have individually been attempted to combine with anti-PD-(L)1 in preclinical and clinical investigation. This review, with a particular focus on pancreatic cancer therapy, collects current anti-PD-(L)1-based combination strategy, highlights potential adverse effects of accumulative combination, and further points out future direction in optimization of combination, including targeting post-translational modification of PD-(L)1 and improving precision of treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据